Clinical trial · Observational
Latin American Real-world Study in Acute Leukemia
Real-world Study in Acute Leukemia: Epidemiology, Treatment Patterns and Outcomes for B-cell ALL and AML in Adult Patients From Latin America - LOYAL Study
NCT05166135CI-TRIAL-00087620LOYALcompletedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoid Leukemia | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Acute Myeloid Leukemia
- description
- Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
- label
- Relapsed/Refractory Acute Lymphoid Leukemia
- description
- Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
Primary outcomes (39)
- measure
- Number of Participants According to Health Insurance Type
- timeFrame
- At index (anytime between 01-Jan-2015 and 31-Dec-2019; approximately 5 years); data collected and observed retrospectively over 11 months
- description
- Number of participants according to type of health insurance (public or private) were reported in this outcome measure.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥18 years old at diagnosis * Confirmed diagnosis of relapsed/refractory B-cell ALL or de novo AML diagnosed between 01 January 2015 and 31 December 2019 * At least 1 line of treatment for R/R B-cell ALL or de novo AML within the study period Exclusion Criteria: * Patients with no medical chart available * Patients with unreliable data as per investigator's opinion (e.g. excessive missing data or inconsistence data) * Patients that have participated in any interventional clinical trial for relapsed/refractory B-cell ALL or AML at any moment * Patients with secondary AML * Patients with any concomitant primary malignancy * Patients with acute promyelocytic leukemia (APL)
References
Publications (0)
Data not yet available
No reference posted for this study.